This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Markus, J. Articles by Wolff, L. Search for Related Content PubMed PubMed Citation Articles by Markus, J. Articles by Wolff, L.

Methylation-Independent Silencing of the Tumor Suppressor INK4b (p15) by CBFß-SMMHC in Acute Myelogenous Leukemia with inv(16)

¹ Laboratory of Cellular Oncology, National Cancer Institute and ² National Human Genome Research Institute, NIH, Bethesda, Maryland and ³ Rush Cancer Institute and ⁴ Department of Medicine, University of Chicago, Chicago, Illinois

Requests for reprints: Linda Wolff, NIH, Building 37, Room 4124, 37 Convent Drive, MSC 4263, Bethesda, MD 20892-4263. Phone: 301-496-6763; Fax: 301-594-3996. E-mail: lwolff{at}helix.nih.gov.

The tumor suppressor gene INK4b (p15) is silenced by CpG island hypermethylation in most acute myelogenous leukemias (AML), and this epigenetic phenomenon can be reversed by treatment with hypomethylating agents. Thus far, it was not investigated whether INK4b is hypermethylated in all cytogenetic subtypes of AML. A comparison of levels of INK4b methylation in AML with the three most common cytogenetic alterations, inv(16), t(8;21), and t(15;17), revealed a strikingly low level of methylation in all leukemias with inv(16) compared with the other types. Surprisingly, the expression level of INK4b in inv(16)+ AML samples was low and comparable with that of the other subtypes. An investigation into an alternative mechanism of INK4b silencing determined that the loss of INK4b expression was caused by inv(16)-encoded core binding factor ß-smooth muscle myosin heavy chain (CBFß-SMMHC). The silencing was manifested in an inability to activate the normal expression of INK4b RNA as shown in vitamin D3–treated U937 cells expressing CBFß-SMMHC. CBFß-SMMHC was shown to displace RUNX1 from a newly determined CBF site in the promoter of INK4b. Importantly, this study (a) establishes that the gene encoding the tumor suppressor p15^INK4b is a target of CBFß-SMMHC, a finding relevant to the leukemogenesis process, and (b) indicates that, in patients with inv(16)-containing AML, reexpression from the INK4b locus in the leukemia would not be predicted to occur using hypomethylating drugs. [Cancer Res 2007;67(3):992–1000]

This article has been cited by other articles:

				C. K. Cheng, L. Li, S. H. Cheng, K. M. Lau, N. P. H. Chan, R. S. M. Wong, M. M. K. Shing, C. K. Li, and M. H. L. Ng Transcriptional repression of the RUNX3/AML2 gene by the t(8;21) and inv(16) fusion proteins in acute myeloid leukemia Blood, October 15, 2008; 112(8): 3391 - 3402. [Abstract] [Full Text] [PDF]